Bilayer Therapeutics
Bilayer Therapeutics: Pioneering constipation therapeutics and colon disease solutions since 2020.
Bilayer Therapeutics: Pioneering constipation therapeutics and colon disease solutions since 2020.
Bilayer Therapeutics, founded in 2020 and headquartered in Cambridge, Massachusetts, is a biotech company dedicated to developing first-in-class therapeutics for constipation and other colon diseases. The company's core mission is to provide innovative and effective treatments for gastrointestinal conditions and metabolic disorders. Bilayer Therapeutics leverages a novel therapeutic approach and a proprietary bilayer delivery system to enhance the efficacy of bile acids, which are crucial modulators of metabolism and motility.
Key figures affiliated with Bilayer Therapeutics include leading experts in biotechnology and gastrointestinal research. The company has attracted significant attention from investors due to its groundbreaking approach and potential to address unmet medical needs. Notable achievements include the development of their proprietary bilayer technology, which promises long-lasting benefits for millions suffering from gastrointestinal issues. Bilayer Therapeutics is poised to make a substantial impact on the healthcare industry by offering better treatment options for patients with chronic gastrointestinal conditions.
Companies similar to Bilayer Therapeutics include Beryl Therapeutics, Bond Biosciences, Faze Medicines and Intact Therapeutics.
Bilayer Therapeutics was founded in 2020.
Bilayer Therapeutics' most recent funding round was for $2M (USD) in April 2021.
As of Apr 28, 2021, Bilayer Therapeutics has disclosed funding of $2M (USD). Undisclosed round amounts are excluded.
Bilayer Therapeutics has 3 employees as of Feb 5, 2024.

Intact Therapeutics